<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A prospective randomized trial was undertaken to compare the efficacy and toxicity of murine antihunman T-cell monoclonal antibody (mcAb) therapy to that of horse antihuman thymocyte globulin (ATG) in the treatment of severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) </plain></SENT>
<SENT sid="1" pm="."><plain>Patients were randomized into one of the two treatment groups as well as to receive or not receive <z:chebi fb="5" ids="50113">androgens</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Median duration of <z:mpath ids='MPATH_58'>aplasia</z:mpath> prior to treatment was 1.5 and 2.2 months for the mcAb and ATG groups, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>One of 12 patients who received mcAb therapy had a partial response, whereas four of 13 patients receiving ATG had a complete or partial response </plain></SENT>
<SENT sid="4" pm="."><plain>Of the 11 patients who failed mcAb treatment, six were subsequently treated with ATG and two improved </plain></SENT>
<SENT sid="5" pm="."><plain>Ten of 13 patients who received ATG are surviving compared with seven of 12 patients who received mcAb </plain></SENT>
<SENT sid="6" pm="."><plain>Toxicity of mcAb therapy was less than that of ATG </plain></SENT>
<SENT sid="7" pm="."><plain>Future studies are needed to determine whether mcAbs known to be immunosuppressive are of benefit as therapy for patients with AA </plain></SENT>
</text></document>